Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients with Chronic Heart Failure and Reduced Ejection Fraction: Insights from the PARADIGM-HF Study (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)

Circulation

Volumn 134, Issue 22, 2016, Pages 1785-1787

  Nadruz, Wilson ^a,b   Claggett, Brian L ^a   McMurray, John J ^c   Packer, Milton ^d   Zile, Michael R ^e   Rouleau, Jean L ^f   Desai, Akshay S ^a   Swedberg, Karl ^g   Lefkowitz, Martin ^h   Shi, Victor C ^h   Prescott, Margaret F ^h   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MONTREAL HEART INSTITUTE   (Canada)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

BNP; heart failure; natriuretic peptides; NT proBNP; obesity; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEINASE INHIBITOR;

ADULT; AGED; BODY MASS; CARDIAC PATIENT; CONTROLLED STUDY; DEATH; FEMALE; HEART FAILURE; HEART VENTRICLE EJECTION; HOSPITALIZATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REDUCED EJECTION FRACTION; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OBESITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; BODY MASS INDEX; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; OBESITY; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84999788889     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024976     Document Type: Letter

References (5)

1. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590-1595.
2. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176:611-617. doi: 10. 1016/j. ijcard. 2014. 08. 007.
3. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol. 2006;47:85-90. doi: 10. 1016/j. jacc. 2005. 08. 050.
4. Frankenstein L, Remppis A, Nelles M, Schaelling B, Schellberg D, Katus H, Zugck C. Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J. 2008;29:2634-2640. doi: 10. 1093/eurheartj/ehn388.
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10. 1056/NEJMoa1409077.